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 Abstract  
 Pharmacological modulation of the transient receptor potential melastatin type 8 (TRPM8) is 
currently under investigation as a new approach mainly for the treatment of pain. In this study, a series 
of N-substituted tryptamines was prepared to explore the structural requirements determining TRPM8 
modulation. As a result of a fluorescence-based screening assay, we identified two compounds acting 
as an activator (2-(1H-indol-3-yl)-N-(4-phenoxybenzyl) ethanamine, compound 21) or an inhibitor 
(N,N-dibenzyl-2-(1H-indol-3-yl) ethanamine, compound 12) of calcium influx in HEK293 cells. In 
patch-clamp recordings, compound 21 displayed a significantly higher potency (EC50 = 40±4 µM) and 
a similar efficacy when compared to menthol; by contrast, compound 12 produced a concentration-
dependent inhibition of menthol-induced TRPM8 currents (IC50 = 367±24 nM). Molecular modelling 
studies using a homology model of a single TRPM8 subunit identified a putative binding site located 
between the VSD and the TRP box, disclosing two different binding modes for the agonist and the 
antagonist. 
 
  
 Introduction 
 Transient receptor potential melastatin type-8 (TRPM8) is a transmembrane, non-selective 
Ca
2+
 permeable cation channel, 
1
 considered as the major sensor for peripheral innocuous cool and its 
modulation contributes to a wide range of physiological and pathophysiological processes. One of the 
most investigated effects produced by TRPM8 modulation is the analgesia against chronic and 
neuropathic pain: in fact, it has been reported that peripheral and central activation of TRPM8 induces 
analgesia, specifically reversing the sensitization of the behavioral reflexes elicited by peripheral 
nerve injury. 
2
 Notably, both TRPM8 agonists and antagonists exert analgesic effects: in particular, 
while TRPM8 agonists produce profound analgesia 
2
 at very low concentrations, even greater effects 
have been reported for TRPM8 antagonists. 
3
 This analgesia modulation represents a novel approach 
in a largely unmet therapeutic need. 
4
 Moreover, many studies have recently revealed novel potential 
pharmacological implications for TRPM8 modulators. For example, TRPM8 agonists have been 
proposed as useful diagnostic and therapeutic tools for the treatment of prostate cancer and benign 
prostate hyperplasia (BPH). 
5, 6
 In fact the activation of TRPM8 receptors enhances apoptosis in 
prostate carcinoma cells, highlighting a potential involvement of this channel in androgen-responsive 
prostate cancer cell growth. Apart from androgen-sensitive prostate cancer, TRPM8 is abnormally 
over-expressed in other tumor malignancies, like breast cancer, 
7, 8
 human pancreatic adenocarcinoma, 
9
 and skin melanoma cells. 
10
 Concurrently, TRPM8 blockers have been investigated for the treatment 
of overactive and painful bladder syndromes. 
11
 In particular, N-(3-Aminopropyl)-2-[(3-
methylphenyl)methoxy]-N-(2-thienylmethyl) benzamide (AMTB), a well-recognized TRPM8 
antagonist, can attenuate the bladder micturition reflex and the nociceptive reflex response in the rat, 
thus decreasing the frequency of volume-induced bladder contraction. 
12
 Finally, TRPM8 modulators 
could be of interest in treating dry eye syndrome and excessive lacrimation dysfunction, due to 
extensive TRPM8 expression in corneal afferent neurons. 
13, 14
 
  For these reasons, increasing efforts have been dedicated, both by academia and industry, to 
the design of TRPM8 ligands starting from different structural scaffolds. 
15-22
 Most of the compounds 
described in the literature showed high potency on TRPM8 channels, although they also show 
agonistic and/or antagonistic properties towards other TRP receptors, such as TRPA1 and TRPV1 
channels. 
23, 24
 Recently, some indole alkaloids have been identified, 
25
 resulting in potent antagonists 
with a pronounced selectivity for TRPM8 when compared to TRPA1 or TRPV1 channels. Also 5-
substituted tryptamines have been studied as potent TRPM8 blockers. 
26
 In addition, in a previous 
work we demonstrated that the potency of TRPM8 ligands could be modulated varying substituents 
on the nitrogen group of the aminoisoxazole scaffold. 
21
 
 On the basis of these findings, we synthesized a focused library of 18 tryptamine-based 
compounds and tested their activity as TRPM8 modulators by performing a fluorescence-based assay 
and patch-clamp recordings. Pharmacological activity was rationalized by molecular modelling 
studies defining basic structural requirements for TRPM8 agonism and antagonism. In addition, 
computational studies allowed the identification of a putative binding site for tryptamine-based 
TRPM8 modulators.  
  
 
Results and Discussion 
Chemistry 
 Derivatives 4-12 were synthesized according the experimental procedure showed in Scheme 1. 
A subset of compounds (4-7, scheme 1) was prepared from the N-1 substituted intermediates 2 and 3. 
Reaction of 3-(2-bromoethyl)-1H-indole (1) with methyl iodide or 4-phenylbenzyl iodide in 
DCM/DMF using NaH as a base, led to derivatives 2 and 3 with 67% and 61% yields, respectively. 
The 4-phenylbenzyl iodide (III, see supplementary information, scheme S1), used in the formation of 
 intermediate 3, was previously prepared from the corresponding biphenyl-4-carboxylic acid as 
reported elsewhere. 
27
 
 
Scheme 1. Synthesis of the N, 2-substituted indolethanamine derivatives 4-12  
 
 
 
Nucleophilic displacement of the bromine atom of 1, 2 and 3 by different commercially available 
amines was performed in THF/TEA using palladium acetate as a catalyst. Under microwave 
conditions the final compounds 4-12 were obtained in 55-75% yield.  
 A different strategy was used for the synthesis of compounds 14-22, which employed  
tryptamine 13 as starting material (Scheme 2). Compound 14 was obtained as racemic mixture by 
nucleophilic substitution reaction of the tosyl derivative of the (1,2,3,4-tetrahydronaphthalen-4-
yl)methanol (VI) with tryptamine (13). This intermediate VI has been synthesized by reducing the 
1,2,3,4-tetrahydronaphthalene-1-carboxylic acid with lithium aluminium hydride, followed by 
 tosylation with 4-methylbenzene-1-sulfonyl chloride (see supplementary information, scheme S1).
28
 
 Reductive amination of different commercially available aldehydes with the tryptamine, using 
sodium triacetoxyborohydride as reductive agent gave the final compounds 15-21 in 51% - 85% 
yields (Scheme 2). 
21 
 Finally, treatment of derivative 21 with methyl iodide using NaH as a base allowed us to 
obtained the dimethyl derivative 22 in 37% yield. 
 
Scheme 2. Synthesis of the N, 2-substituted indolethanamine derivatives 14-22 
 
 Screening of the activity of the synthesized compounds by Ca
2+
-imaging experiments 
 To investigate the potential agonistic or antagonistic properties on TRPM8 channels, all 
synthesized compounds were tested at three different concentrations (0.5, 5 and 50  M) by in vitro 
Ca
2+ 
fluorometric assays experiments using Fluo4-NW in HEK293 cells stably expressing mouse 
TRPM8 channels. The results obtained are normalized to the effects prompted by 100 M of the 
canonical agonist menthol 
29
 or by 10 M of the TRPM8 antagonist AMTB + 100 M menthol, 11 
whose effects were reported as + 100% (activation) or -100% (inhibition), respectively (Figures 1A and 
1B).  
 As reported in Figure 1A, compounds 4 and 5 showed agonist activity at high concentration (50 
M), being about 2-fold more effective than menthol. At the same concentration, the presence of the 
sterically hindered biphenyl ethyl group on the amine moiety (6), led to slight loss of efficacy in 
comparison to 4 and 5, maintaining an efficacy similar to menthol. Interestingly, introduction of a 
sterically hindered group at N-1 indole position, such as a biphenyl methyl group, together with 
increased flexibility of the substituent on the amine moiety (7 versus 4 or 5) maintained agonistic 
efficacy .  
 The non-substituted N-1 indole derivatives (8-21) were quite productive. A direct linkage of the 
amine moiety with different bulky aromatic groups, such as naphthalene and quinolines, gives 
compounds 8-11 unable to act as TRPM8 modulators (Figures 1A and 1B). By contrast, the tertiary 
amine obtained by derivatization of tryptamine with a benzyl moiety (12) proved to be an effective and 
potent antagonist. Introduction of a methylene spacer between amine group and bulky aryl moiety in 8 
led to the potent agonist 15, which showed to be 3-fold more effective than menthol at 50 M. 
Introduction of substituents at position 2 of naphthalene ring, such as OMe (16) and OH (17) induced a 
shift from agonist to antagonistic activity for these derivatives at high concentration (Fig. 1 B). A 
 similar effect was observed when the bicyclic system modification involves changes in the electronic 
nature of the ring (14) or an increase in ring size (18). In addition, tryptamine benzyl derivatives 19 and 
20 lost the agonistic activity shown by the methylated analogue 4.  
 Notably, compound 21 bearing a p-methoxybenzyl group showed significant agonist activity at 
0.5 M, with a similar efficacy to that of menthol. At 50 M, the efficacy of derivative 21 was nearly 
3-fold higher than that of menthol. Conversion of this compound to its N-methyl-2-(1-methyl-1H-
indol-3-yl)-derivative (22) shifted the agonistic activity to antagonism, with an efficacy comparable to 
that of derivative 12, at all tested concentrations (Figure 1B). 
 
 
  
Figure 1: Efficacy of synthesized compounds as TRPM8 agonists (panel A) or antagonists (panel B) at three different 
increasing concentrations (0.5 µM, 5 µM, and 50 µM). Values are expressed as mean±SEM of 3 independent 
measurements. 
 
 To investigate the ability of newly-described TRPM8 modulators to interfere with the activity 
of other TRP channels, particularly TRPV1 and TRPA1, two TRPM8 antagonist (12, 22) and one 
agonist (21), were also tested in calcium fluorometric experiments in SH-SY5Y cells stably expressing 
mouse TRPV1 channels and in IMR90 cells natively expressing mouse TRPA1 channels. In this 
experiment the canonical TRPV1 agonist (capsaicin, 10 M) or antagonist (ruthenium red, 10 M) as 
well as the canonical TRPA1 agonist (AITC, 500 M) or antagonist (ruthenium red, 10 M) were used 
 as controls. The values obtained for the tested compounds were normalized to the effects exerted by 
canonical agonists or agonist + antagonist co-exposure.  
 As reported in Figure 2, compound 12 appeared a rather selective TRPM8 antagonist, showing 
weak activity on TRPV1 only at the highest concentration (Figure 2A), and unremarkable activity on 
TRPA1 at all concentrations (Figure 2B). Interestingly, the TRPM8 agonist 21 behaved instead as an 
antagonist on both TRPV1 and TRPA1 receptors in study, showing in both, full antagonist ability at the 
highest concentrations (50 M; Figs. 2A and 2B). Compound 22 appeared less selective, acting as an 
antagonist of both TRPV1 (Fig. 2A) and TRPA1 (Fig. 2B) channels with potency comparable to that on 
TRPM8 at all concentrations, and was therefore not further investigated . 
 
  
Figure 2: Efficacy of synthesized compounds at three different increasing concentrations (0.5 µM, 5 µM  and 50 µM) as 
modulators of TRPV1 (vs capsaicin and capsaicin + ruthenium red, panel A) and TRPA1 (vs AITC and AITC + ruthenium 
red,  panel B). Value are expressed as mean±SEM of 3 indipendent measurements. 
 
 
Pharmacological properties of derivatives 21 and 12 characterized by patch-clamp 
electrophysiology  
 
 The previously described multicellular functional assay identified derivatives 21 and 12 as the 
most effective and potent agonist and antagonist compounds, respectively, on TRPM8 channels. To 
provide direct evidence for this activity, derivatives 21 and 12 were tested in single HEK-293 cells 
 transiently expressing the rat TRPM8 isoform by patch-clamp recordings using a 100-msec voltage 
ramp ranging from -100 mV to +100 mV delivered every 4 sec. Perfusion with 500 µM menthol 
activated a large, strongly outwardly-rectifying (I+80 mV/I-80 mV of 90±25; n=39) reversing at a potential 
near 0 mV (-1.3±0.7 mV; n=10) (Figures 3A and 3B). No currents were activated when menthol was 
perfused on non-transfected cells (0 pA/pF at +80 mV; n=4; data not shown). The dose-response curve 
at +80 mV of menthol-evoked currents (Figure 3C) showed an EC50 of 75±4 µM, a value close to those 
for rat 
30
 and mouse isoforms. 
31,32
  
 Perfusion of derivative 21 (100 µM) in rTRPM8-transfected HEK-293 cells also triggered the 
appearance of large outwardly rectifying currents, reversing around 0 mV (-1.1±0.3 mV; n=10; Figures 
3D and 3E). By contrast, perfusion of derivative 12 (100 µM) fails to activate TRPM8 current (data not 
shown). When compared to menthol, derivative 21 displayed a significantly higher potency (EC50 was 
40±4 µM; n =3-10) and a similar efficacy (pA/pF at +80 mV were 134±13 or 140±7 for menthol; p > 
0.05) (Figure 3F). Notably, the presence of the 1-methyl-4-phenoxybenzene group in this derivative 
(Scheme 2) appears to be crucial for TRPM8 activation, as the derivative 11 which carries an 
isoquinoline group showed no agonist activity (0 pA/pF at +80 mV; n=4; data not shown), as also 
suggest by fluorescence assay (Figure 1A). 
 
  
Figure 3: Menthol- and derivative 21-induced currents in HEK293 cells expressing TRPM8. A, D) Representative traces of 
currents evoked by a 100-ms voltage ramp ranging from -100 mV to +100 mV applied every 4 sec, in control solution 
(CTL; black trace; A,D), during application of menthol (green trace; A) or derivative 12 (gray trace; D) or after washout 
(W; red trace; A,D). B, E) Time-course of currents recorded at +80 mV (blue symbols) or -80 mV (red symbols) in single 
HEK293 cells expressing TRPM8 upon exposure to menthol (500 µM; B) or derivative 12 (100 µM; E). The duration of 
compounds exposure is indicated by the bar on top of the traces. C, F) Concentration–response curves for TRPM8 current 
activation by menthol (C) or derivative 12 (F). Peak current data were expressed as pA/pF (to facilitate comparison among 
cells of different sizes), and expressed as a function of agonist concentrations. The solid lines represent fits of the 
experimental data to the following binding isotherm: y = max/(1 + x/EC50)
n
, where x is the drug concentration and n the Hill 
coefficient. The fitted values for n were 0.97 ± 0.05 or 3.0 ± 0.6 for menthol or derivative 12, respectively. Each point is the 
mean ± SEM of 4–13 (for menthol) or 3-10 (for derivative 12) determinations, each obtained in different cells. 
 
 
 
 To investigate possible antagonistic effects exerted by the newly-synthesized compounds, we 
investigated their ability to inhibit menthol-evoked responses. As previously reported, the canonical 
TRPM8 antagonist BCTC (3 µM) produced a fast and complete inhibition of menthol-gated TRPM8 
currents, which largely recovered after drug washout (Figures 4A and 4B). 
33
 Similarly, perfusion of 
the same concentration of derivative 12, produced a complete inhibition of menthol-induced TRPM8 
currents measured at +80 mV (Figures. 4C and 4D), with kinetics slower than that observed for BCTC. 
 This block appears concentration-dependent, with an IC50 of 367±24 nM (n=3-9;), a value slightly 
lower than that reported for BCTC (475 nM) 
33
. These effects were largely reversible upon drug 
washout (Figure 3C), although with much slower kinetics when compared to those observed for BCTC. 
 
 
Figure 4: BCTC and derivative 12 block TRPM8-mediated responses evoked by menthol in TRPM8-expressing HEK293 
cells. A, C) Time-course of currents recorded at +80 mV or -80 mV in HEK293 cells expressing TRPM8 upon application 
of 500 µM menthol (A,C), 500 µM menthol + 3 µM BCTC (A) or 500 µM menthol + 3 µM derivative 12 (C). B, D) I–V 
curves obtained in HEK293 cells expressing TRPM8 and exposed to control solution (CTL; black trace; B,D), 500 µM 
menthol (green trace; B,D), 500 µM menthol + 3 µM BCTC (red trace; B) or to 500 µM menthol + 3 µM derivative 12 (red 
trace; D). Traces shown in B, D correspond to the currents measured at the time points shown in colors (green or red circles) 
in A, C. 
 
 
Molecular modeling and structural rationale 
 In a recent paper, Taberner et al. reported the central role of S6-TRP box linker (amino acids 
980–992 in rat TRPM8) in the gating mechanism of TRPM8 channel.34 As shown by their homology 
models based on the experimentally solved structures of TRPV1, the conformational changes in the 
 voltage sensors by activating stimuli could be associated to a widening of the S6 C-end, which in turn 
might disrupts the intersubunit interactions in the region of Tyr981, thus favoring channel opening.
35
 
 We ran a series of simulations to investigate whether a TRPM8 monomer was able to bind the 
newly-synthesized small molecules and to test the influence of this binding on the conformation of the 
functional 980-992 region. We ran SiteMap 
36 
calculations on the whole monomer to detect potential 
binding sites. The best site identified (BP1 – Figure S1), has a volume of 791 Å and a site score of 
1.093 (the cutoff value generally used to distinguish between drug-binding and non-drug-binding sites 
is 0.80), and is located between S1, S2, S3, and S4 helices, while at the bottom is delimited by residues 
990-1010. The proximity of the binding site to the 980-992 region suggests that the binding of a 
molecule to BP1 might influence the conformation of this linker region in the TRP domain pivotal for 
coupling stimuli sensing to pore opening. We ran automated molecular docking simulations to predict 
the binding mode into BP1 of the most potent antagonist (12) and agonist (21) in our series. The best-
docked models were then submitted to 12 ns long molecular dynamics simulations to analyze protein-
ligand contacts and protein conformational rearrangements at the level of BP1 and of the 980-992 
region.  
 BP1- 12 and BP1- 21 complexes are stabilized by similar interactions, such as hydrophobic 
contacts with Leu843, Ile701, Leu697, π-π stacking with Tyr754 and electrostatic interactions with the 
Glu1004 side chain . A part from these similar interactions, the antagonist and the agonist also show 
different interactions that could be responsible for different conformational rearrangements of the 980-
992 region. In particular, 21 makes a hydrogen bond with the phenoxyl group of Tyr754 by its amino-
linker and a second hydrogen bond, with the backbone of Arg1008, provided by the indole NH (see 
figure S2A). The different interaction of 12 or 21 to TRPM8 possibly brings to differences in the 
conformation of BP1, regarding in particular Arg1008. In the closed model of TRPM8 (APO), 
Arg1008 is projected into BP1, stabilized by hydrogen bonds with Glu1004 and Tyr754 (Figure 5A). 
 Upon 21 binding this arginine side chain appears projected outside of BP1 (Figure 5B), with the ligand 
indole ring claiming its space and hydrogen binding to Arg1008 backbone. Compound 21 makes 
further hydrogen bonds with the side chain carboxyl of Glu1004, which is shifted away from the 
position it has in the APO closed model, and with the hydroxyl group of Tyr754. Therefore, the binding 
of 21 caused an increase in the Arg1008-Glu1004 distance when compared to that measured in the 
APO TRPM8 configuration (Figure 5D). This conformational rearrangement at the bottom of BP1 
prompts an evident shift of the TRP domain helix, that makes the conformation of the 980-992 region 
looser and prone to rearrange as described below. In the case of 12 binding, Arg1008 is instead 
pointing again toward the BP1 cavity, keeping its interaction with Glu1004 as in the APO form 
(Figures 5C-D).  
 
 
Figure 5: Arg1008 hydrogen bond network (in yellow dashes) in Apo TRPM8 (A) and its changes upon ligand binding: (B) 
21 bound conformation of TRPM8 is depicted in cyan, ligand in yellow sticks and apo TRPM8 is depicted in green as 
reference. (C) 12 bound conformation of TRPM8 is depicted in green, 12 in yellow sticks and 21 bound TRPM8 is depicted 
in cyan as reference. Arg1008-Glu1004 distances (D) and 980-992 region RMSDs (E) recorded during 12ns long MD 
trajectories. 
 
 Moreover, this compound establishes a wider hydrogen-bonding network, interacting even with 
Gln1003 and Glu662, possibly stabilizing the TRP domain helix and causing the antagonism shown by 
the ligand. Indeed, looking at the RMSD of the 980-992 region as a function of time and of the bound 
ligand (Figure 5E), it is evident that the conformation of TRPM8/12 is much closer to the APO TRPM8 
than TRPM8/21. This behavior indicates that the binding of 21 makes the 980-992 region prone to 
conformational rearrangement events.  
We used the predicted bioactive conformations of 12 and 21 to summarize the most stable interactions 
involved in the binding of these ligands as representative antagonists and agonists of this tryptamine-
based series (Figure 6). The pharmacophore model for tryptamine-based agonists accounts for the 
interaction with Ile837, Leu806, Ile701 (H1), Leu697, Leu843, Ile844 (H2), Glu1004 (D2/P1), 
Arg1008 (D3), Tyr754 (D1/R1), and Leu757 and Met758 (R1) (Figure 6A).  
 
Figure 6. Pharmacophore models for tryptamine-based TRPM8 agonists (A) and antagonists (B). Chemical features are 
depicted as spheres and color-coded as follows: yellow, H = hydrophobic, blue, P = positive charge, green, D = HB donor, 
orange, R = aromatic ring. 21 and 12 are represented as references in panels A and B, respectively. 
 
On the other hand, the antagonist model accounts for the interaction with Ile701, Leu751, Leu697, 
Leu843 (R1), Glu1004 (P1/D1), Val800 (H1), Arg1008 (R2) and Tyr754 (R1/R2) (Figure 6B). The two 
pharmacophore models might help to understand which chemical features are required to endow a 
 ligand with agonist or antagonist capabilities. Despite binding to the same site, the two models present 
in fact substantial differences that may cause the observed differences induced in TRPM8 
conformation. All the agonists reported in this paper fit, at least in part, the agonist model. All of them 
in fact place correctly D1/P1, D2 (compounds 4, 5, 6, 7, 15, and 21) and H1 features (21). R1 location 
is always occupied by a large substituent claiming the space of Arg1008 side chain and in same cases 
this moiety engages in HB with the Arg1008 backbone. By contrast R2 antagonist feature has to be, 
when present, a small substituent that does not occupy the Arg1008 room. H1 is probably the feature 
that boosts the activity of 21, since it is the only one that perfectly fits it. Regarding the antagonists 
model, H1, P1 and D1 seem to be the mandatory feature for exerting antagonism (compounds 12 and 
both conformers of 22), while R1 could boost activity by π-π interaction with Tyr754, and a 
relatively small R2 substituent could be engaged, by its π cloud, in interaction with Tyr754 and the 
positively charged Arg1008 side chain, improving its antagonist capabilities. Looking at the fittings of 
the tryptamine-based agonists and antagonists sets, it seems that the mandatory features to exert 
agonism are H2, P1, D1 and D2, while on the other side H1, P1 and D1 are necessary for the 
antagonists (see Table S1).  
 
Conclusions 
Here we report the synthesis and pharmacological evaluation of a small library based on the tryptamine 
scaffold designed as TRPM8 ion channel modulators. Two of the synthesized derivatives, compounds 
12 and 21, showed to be efficient and potent TRPM8 antagonist and agonist, respectively. In fact, 12 
produced a complete inhibition of menthol-induced TRPM8 currents with a higher potency than that 
reported for the well-known TRPM8 antagonist BCTC. Meanwhile the agonist 21 showed a 
significantly higher potency and efficacy than menthol. In addition, compound 12 showed 
 unremarkable activity on TRPV1 and TRPA1 at different concentrations while the agonist 21 behaved 
as an antagonist on both TRPV1 and TRPA1 receptors at high concentration.  
Computational studies allowed us to hypothesize a binding site and two pharmacophore prototypes for 
this series of tryptamine-based TRPM8 modulators. The proposed structural model identifies the same 
binding site for agonist and antagonist, but two binding modes differing in the “interaction network”. 
Since structural models have to be used with caution, further investigations are needed to confirm the 
structural hypothesis. The results of this study provide valuable information for the future design of 
new and specific TRPM8 modulators that could be useful in the treatment of different diseases 
involving a deregulation of this ion channel. 
Experimental section 
General. Reagents, starting materials, and solvents were purchased from Sigma-Aldrich (Milan, Italy) 
and used as received. Reactions were carried out with magnetic stirring in round-bottomed flasks 
unless otherwise noted. Moisture-sensitive reactions were conducted in oven-dried glassware under a 
positive pressure of dry nitrogen, using pre-dried, freshly distilled solvents. Microwave assisted 
reactions were performed in a Biotage Initiator
+
 reactor. Analytical thin layer chromatography (TLC) 
was performed on pre-coated glass silica gel plates 60 (F254, 0.25 mm, VWR International). 
Purifications were performed by flash column chromatography on silica gel (230-400 mesh, Merck 
Millipore). NMR spectra were recorded on Varian Mercury-400 apparatus. 
1
HNMR and 
13
C NMR 
spectra were recorded with a Varian-400 spectrometer, operating at 400 and 100 MHz, respectively. 
Chemical shifts are reported in δ values (ppm) relative to internal Me4Si, and J values are reported in 
hertz (Hz). The following abbreviations are used to describe peaks: s (singlet), d (doublet), dd (double 
double), t (triplet), q (quadruplet) and m (multiplet). ESI-MS experiments were performed on an 
Applied Biosystem API 2000 triple-quadrupole spectrometer. Combustion microanalyses were 
 performed on a Carlo Erba CNH 1106 analyzer, and were within 0.4% of calculated values and 
confirmed >95% purity for the final products. Analytical RP-HPLC was performed on a Phenomenex 
Synergi Fusion RP-80A (75 x 4.6 mm, 4 M), with a flow rate of 1 ml/min, using a tunable UV 
detector at 254 nm. Mixtures of CH3CN and 0.05% TFA in H2O were used as mobile phase. 
 
General procedure for the synthesis of derivatives 2 and 3. 
3-(2-Bromoethyl)indole (1, 1.0 eq) was dissolved in a mixture of anhydrous DCM/DMF (2/1 v/v) 
under magnetic stirring and the temperature was set to 0°C. To this solution, 1.5 equivalents of NaH 
were added portionwise and the mixture was allowed to react for 30 minutes. Then, 1.5 equivalents of 
alkyl iodide [methyl iodide or 4-[phenyl]iodomethylbenzene (III)] in DCM were added dropwise  and 
the reaction was warmed to room temperature and maintained under stirring for further 12h. Then, 
reaction was quenched by 10% aqueous solution of citric acid and washed with brine. Organic layer 
was separated, dried over anhydrous Na2SO4, filtered and evaporated in vacuo. Crude products were 
purified by column chromatography using n-hexane/ethyl acetate (4:1 v:v) as mobile phase. 
3-(2-Bromoethyl)-1-methyl-1H-indole (2).  
Yield 67%. 
1
H NMR (400 MHz,CDCl3) δ 3.39-3.46 (m, 4H, CH2); 3.79 (s, 3H, CH3); 6.97 (s, 1H); 
7.20 (t, 1H, J = 7.6 Hz); 7.28 (d, 1H, J = 8.0 Hz); 7.34 (t, 1H, J = 8.0 Hz); 7.62 (d, 1H, J = 8.0 Hz). 
ESIMS m/z calcd for C11H12BrN, 237.02; found 238.11 (M+H
+
) 
Synthesis of 1-(Iodomethyl)-4-phenylbenzene intermediate (III). 
To one equivalent of biphenyl-4-carboxylic acid (I) dissolved in dry THF was added portionwise 
LiAlH4 (3.0 eq), under stirring at room temperature (Scheme 2). After 2 hours the solution was washed 
three times with HCl 2N and then water and the organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The resultant 4-biphenylmethanol (II) was purified by flash chromatography 
 using ethyl acetate as solvent and was obtained as oil in 89% yield. 
1
H NMR (400 MHz,CDCl3) δ 2.98 
(bs, 1H, OH); 4.70 (s, 2H, CH2); 7.33-7.43 (m, 5H, aryl); 7.59-7.61 (m, 4H, Aryl).  
Then, treatment of II with triphenylphosphine and I2, in dry DCM, according to the procedure 
previously described, 
27
 gave the title compound in 65% yield. 
1
H NMR (400 MHz,CDCl3) δ 4.53 (s, 
2H, CH2); 7.15 (d, 2H, J = 8.0 Hz); 7.24 (d, 2H, J = 8.0 Hz); 7.43-7.55 (m, 5H).  
1-(Biphenyl-4-ylmethyl)-3-(2-bromoethyl)-1H-indole (3).  
Prepared from intermediate III and 3-(2-bromoethyl)indole as described above. Yield 61%. 1H NMR 
(400 MHz,CD3OD) δ 3.27 (t, 1H, J = 7.4 Hz, CH2); 3.38-3.46 (m, 2H, CH2); 3.81 (t, 1H, J = 7.6 Hz, 
CH2); 5.35 (s, 2H, CH2); 7.07 (s, 1H); 7.14-7.61 (m, 13H). ESIMS m/z calcd for C23H20BrN, 391.08; 
found 392.13 (M+H
+
). 
General procedure for the synthesis of derivatives 4-12. 
One equivalent of 3-(2-bromoethyl)indole (1) or intermediate 2 or 3 was dissolved in THF and 1.5 eq 
of the proper amine, 1.5 eq of TEA, 1.5 eq of NaI and 0.3 eq of (CH3COO)2Pd were added to this 
solution (Scheme I). The reaction was conducted under W, at 100°C, for 20 minutes. The resulting 
mixture was filtered through Celite, dried in vacuo and reconstituted in DCM. The organic phase was 
washed with water (3 x 50 mL), dried over anhydrous Na2SO4, filtered, concentrated and purified by 
column chromatography using DCM/MeOH as mobile phase.  
N-(4-Methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)ethanamine (4) 
Synthesized starting from 3 and 4-methoxybenzylamine, yield 71%. 
1
H NMR (400 MHz,CDCl3) δ 2.92 
(t, 2H, J = 7.6 Hz, CH2); 3.19 (t, 2H, J = 7.6 Hz, CH2); 3.49 (s, 6H, 2CH3); 3.72 (s, 2H, CH2); 6.81 (s, 
1H); 7.07-7.15 (m, 3H); 7.20 (t, 1H, J = 6.8 Hz); 7.24-7.30 (m, 3H); 7.52 (d, 1H, J = 8.0 Hz). 
13
C NMR 
(100 MHz, CDCl3) δ 22.7, 41.6, 50.8, 57.1, 109.1, 110.0, 112.4, 118.6, 118.8, 121.4, 121.9, 124.2, 
126.4, 128.0, 128.3, 135.3, 199.8. ESIMS m/z calcd for C19H22N2O, 294.17; found 295.20 (M+H
+
). 
N-(4-Chlorobenzyl)-2-(1-methyl-1H-indol-3-yl)ethanamine (5) 
 Synthesized starting from 3 and 4-chlorobenzylamine, yield 69%. 
1
H NMR (400 MHz,CDCl3) δ 2.93-
3.00 (m, 4H, 2CH2); 3.74 (s, 3H, CH3); 3.77 (s, 2H, CH2); 6.87 (s, 1H); 7.10 (t, 1H, J = 8.0 Hz); 7.20-
7.30 (m, 6H); 7.58 (d, 1H, J = 8.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 25.57, 32.56, 49.40, 53.06, 
109.2, 110.0, 112.3, 118.7, 118.9, 121.6, 126.7, 127.8, 128.4, 129.4, 132.5, 137.1, 138.7. ESIMS m/z 
calcd for C18H19ClN2, 298.12; found 299.17 (M+H
+
). 
2-([1,1'-Biphenyl]-4-yl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)ethanamine (6).  
Synthesized starting from 3 and 2-(4-biphenyl)ethylamine, yield 65%. 
1
H NMR (400 MHz,CD3OD) δ 
3.03 (t, 2H, J = 8.8 Hz, CH2); 3.17 (t, 2H, J = 8.6 Hz, CH2); 3.32-3.37 (m, 4H, CH2); 3.76 (s, 3H, CH3); 
7.06-7.11 (m, 2H); 7.20 (t, 1H, J = 7.2 Hz); 7.31-7.44 (m, 6H); 7.56-7.60 (m, 5H). 
13
C NMR (100 
MHz, CD3OD) δ 22.0, 31.7, 48.4, 109.4, 118.0, 119.0, 121.8, 126.7, 127.3, 127.5, 128.7, 129.1, 135.5. 
ESIMS m/z calcd for C25H26N2, 354.21; found 355.26 (M+H
+
).  
2-(1-([1,1'-Biphenyl]-4-ylmethyl)-1H-indol-3-yl)-N-(3,4-dimethoxyphenethyl)ethanamine (7). 
Synthesized starting from 3 and 3,4-dimethoxyphenthylamine, yield 75%. 
1
H NMR (400 
MHz,CD3OD) δ 2.91 (t, 2H, J = 7.2 Hz, CH2); 3.17-3.26 (m, 4H, CH2); 3.34 (t, 2H, J = 7.4 Hz, CH2); 
3.77 (s, 3H, OCH3); 3.79 (s, 3H, OCH3); 5.39 (s, 2H, CH2); 6.83-6.87 (m, 2H); 7.09 (t, 1H, J = 8.0 Hz); 
7.11-7.24 (m, 5H); 7.37-7.41 (m, 4H); 7.50-7.55 (m, 4H); 7.62 (d, 1H, J = 8.0 Hz). 
13
C NMR (100 
MHz, CD3OD) δ 22.1, 31.7, 48.8, 49.2, 55.2, 109.2, 110.1, 112.1, 112.3, 118.3, 119.3, 120.9, 112.0, 
126.7, 126.9, 127.0, 127.2, 127.4, 127.7, 128.7, 129.0, 137.3, 140.7, 148.6 149.6. ESIMS m/z calcd for 
C33H34N2O2, 490.26; found 491.31 (M+H
+
). 
N-[2-(1H-Indol-3-yl)ethyl]naphthalen-1-amine (8).  
Synthesized starting from 1 and 1-naphtalenlamine, yield 55%.
1
H NMR (400 MHz, CDCl3)  3.26 (t, 
2H, J = 8.0 Hz, CH2); 3.64 (t, 2H, J = 8.2 Hz, CH2); 6.70 (d, 1H, J=7.8 Hz); 7.06 (s, 1H); 7.20 (t, 1H, 
J=7.2 Hz); 7.25-7.27 (m, 2H); 7.37-7.43 (m, 4H); 7.66 (d, 1H, J= 7.6 Hz); 7.72 (d, 1H, J=8.0 Hz); 7.80 
(d, 1H, J=8.2 Hz); 7.98 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 25.1; 44.3; 104.7, 111.5; 113.6; 
 117.5, 119.0, 119.8, 120.1, 122.3; 122.5; 123.7; 124.8, 125.9, 126.9; 127.6; 128.9; 133.4; 136.7, 143.7. 
ESI-MS m/z calcd for C20H18N2, 286.15; found 287.20 (M+H
+
). 
N-[2-(1H-Indol-3-yl)ethyl]naphthalen-2-amine (9). 
Synthesized starting from 1 and 2-naphtalenlamine, yield 58%.
1
H NMR (400 MHz, CDCl3)  3.16 (t, 
2H, J = 7.8 Hz CH2); 3.58 (t, 2H, J = 8.0 Hz, CH2); 6.81-6.85 (m, 2H); 7.08 (s, 1H); 7.12-7.24 (m, 4H); 
7.33-7.40 (m, 3H); 7.59 (d, 1H, J=8.4 Hz); 7.64 (d, 1H, J=8.2 Hz); 8.07 (s, 1H, NH). 
13
C NMR (100 
MHz, CDCl3) δ 25.1; 44.1; 104.8, 111.4, 118.4, 119.0, 119.7 122.1, 122.3; 122.4; 123.0; 126.1; 126.5; 
126.8; 127.4; 127.8; 129.1; 133.7; 136.5; 146.0. ESI-MS m/z calcd for C20H18N2, 286.15; found 287.17 
(M+H
+
). 
2-(1H-Indol-3-yl)-N-(quinolin-5-yl-methyl)ethanamine (10). 
Synthesized starting from 1 and 5-aminoquinoline, yield 63%.
 1
H NMR (400 MHz, CDCl3)  3.26 (t, 
2H, J = 8.0 Hz, CH2); 3.62 (t, 2H, J = 8.2 Hz, CH2); 6.82 (d, 1H, J=7.6 Hz); 7.12-7.48 (m, 7H); 7.69 (d, 
1H, J=7.8 Hz); 8.15 (s, 1H, NH); 8.37 (d, 1H, J=4.0 Hz); 9.13 (d, 1H, J=4.0 Hz). 
13
C NMR (100 MHz, 
CDCl3) δ 24.9; 44.1; 107.9; 111.6; 113.0; 113.6, 116.2; 118.9; 119.4; 119.8, 122.3; 122.6; 127.4; 128.4; 
136.5; 138.7; 141.9; 146.6, 153.0. ESI-MS m/z calcd for C19H17N3, 287.14; found 288.26 (M+H
+
). 
2-(1H-Indol-3-yl)-N-(isoquinolin-5-ylmethyl)ethanamine (11). 
Synthesized starting from 1 and 5-aminoisoquinoline, yield 67%. 
1
H NMR (400 MHz, CDCl3)  3.23 
(t, 2H, J = 6.4 Hz, CH2); 3.61 (t, 2H, J = 6.2 Hz, CH2); 7.82 (d, 1H, J=8.0 Hz); 7.15-7.54 (m, 7H); 7.71 
(d, 1H, J=8.0 Hz); 8.11 (s, 1H, NH); 8.39 (d, 1H, J=7.2 Hz); 9.17 (s,1H). 
13
C NMR (100 MHz, CDCl3) 
δ 25.9; 49.9; 111.4; 114.9; 116.9, 119.0, 119.5, 122.3, 122.4, 127.0; 127.3; 127.5; 127.7; 130.1; 134.7; 
134.9; 135.4; 136.6; 143.3; 153.2. ESIMS m/z calcd for C19H17N3 287.14; found 288.24 (M+H
+
). 
N,N-Dibenzyl-2-(1H-indol-3-yl)ethanamine (12).  
Synthesized starting from 1 and dibenzylamine, yield 73%. 
1
H NMR (400 MHz, CDCl3) 2.84 (t, 2H, 
J = 5.6 Hz, CH2); 3.01 (t, 2H, J = 6.0 Hz, CH2); 3.73 (s, 4H, 2CH2); 6.90 (s, 1H); 7.06 (t, 1H, J = 8.2 
 Hz, aryl); 7.18 (t, 1H, J = 8.0 Hz); 7.26 (t, 2H, J = 8.4 Hz); 7.32-7.35 (m, 5H); 7.40-7.43 (m, 5H); 7.85 
(s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 23.3; 54.1; 58.5; 111.2; 114.8; 119.1, 119.3, 121.6, 122.0 
127.0; 127.8; 128.4; 129.0; 136.4; 140.1. ESI-MS m/z calcd for C24H24N2, 340.19 found 341.27 
(M+H
+
). 
Synthesis of N-[(1,2,3,4,Tetrahydronaphthalen-1-yl)methyl]-2-(1H-indol-3-yl)ethanamine (14). 
(1,2,3,4-Tetrahydronaphthalen-1-yl)methyl 4-methylbenzenesulfonate (VI) 
 (1,2,3,4-Tetrahydronaphthalen-1-yl)methanol (V) was synthesized by reduction of 1,2,3,4-
tetrahydronaphthalen carboxylic acid following the procedure described for intermediate II. Yield 95% 
1
H NMR (400 MHz,CDCl3) δ 1.80-1.89 (m, 2H, CH2); 2.02-2.11 (m, 2H, CH2); 2.79-2.90 (m, 3H, CH2 
and CH); 3.90-3.96 (m, 2H, CH2O); 7.12-7.23 (m, 4H).  
Then, to a solution of V in DCM was added Cl-Tos (2.0 eq), TEA (2.0 eq), and DMAP (0.7 eq). After 2 
hour at room temperature, the solution was washed with brine. The organic layer was dried over 
anhydrous Na2SO4, filtered, concentrated and purified with flash chromatography in n-Exane/Ethyl 
acetate 30:20. The title compound VI was obtained in 61% yield. 
1
H NMR (400 MHz, CDCl3) δ 1.67-
1.73 (m, 2H, CH2); 1.85-1.91 (m, 2H, CH2); 2.48 (s, 3H, CH3); 2.68-2.74 (m, 2H, CH2); 3.18 (t, 1H, J = 
8.0 Hz, CH); 4.07 (t, 1H, J = 7.8 Hz, CH2O); 4.21-4.26 (m, 1H, CH2O); 7.05-7.13 (m, 4H); 7.36 (d, 2H, 
J = 8.0 Hz, tosyl); 7.86 (d, 2H, J = 8.0 Hz, tosyl).  
N-[(1,2,3,4,Tetrahydronaphthalen-1-yl)methyl]-2-(1H-indol-3-yl)ethanamine (14). 
A 10 mL sealable flask, equipped with a stir bar, was charged with 1 eq of tosylate VI, and 2.6 eq of 
tryptamine (13, Scheme 3), dissolved in THF. The flask was sealed, heated to 60–70°C, and allowed to 
stir at that temperature overnight. The resulting slurry was cooled to room temperature, added with 
DCM and washed with brine. The organic layer solvents was dried over Na2SO4, filtered and 
evaporated under vacuum. The resulting mixture was separated by silica gel chromatography using 
DCM/MeOH 9/1 as eluent. Yield 69%. 
1
H NMR (400 MHz, CDCl3)  1.68-1.71 (m, 2H, CH2); 1.82-
 1.85 (m, 2H, CH2); 2.65-2.68 (m, 2H, CH2); 3.02-3.05 (m, 2H, CH2); 3.25-3.29 (m, 5H, CH and 2CH2); 
6.96 (d, 1H, J=8.0 Hz); 7.00-7.14 (m, 5H); 7.21 (t, 1H, J = 8.4 Hz); 7.36 (d, 1H, J=8.2 Hz); 7.62 (d, 
1H, J=8.4 Hz); 8.08 (s, 1H, NH);
 13
C NMR (100 MHz, CDCl3) δ 19.2; 22.8; 26.1; 29.3; 36.0; 49.1; 
54.1; 111.6; 113.0; 118.8, 120.0, 122.9, 123.1, 126.2, 126.8, 127.5, 128.7, 129.8; 136.0; 136.9, 143.7. 
ESIMS m/z calcd for C21H24N2, 304.19; found 305.43 (M+H
+
) 
General procedure for the synthesis of derivatives (15-22). 
Tryptamine (1.0 eq) was dissolved in a solution of DCM:CH3COOH (5:1 v/v) at room temperature. To 
this solution 2.0 equivalents of the proper aldheyde were added and the mixture was warmed to reflux 
for 1.5h. Then, 1.8 equivalents of sodium triacetoxyborohydride were added portionwise and the 
mixture was allowed to reflux for further 3-5h. After cooling to room temperature, NaOH 1N was 
added. The organic phase was separated and extracted one more time with the alkaline solution. Then it 
was dried over Na2SO4, filtered and concentrated in vacuo. The crude products were purified by 
column chromatography using mixtures of DCM/MeOH as eluent. 
2-(1H-Indol-3-yl)-N-(naphthalen-1-ylmethyl)ethanamine (15). 
Synthesized starting from 13 and 1-naphthaldehyde, yield 75%. 
1
H NMR (400 MHz,CDCl3) δ 3.05 (t, 
2H, J = 6.8 Hz, CH2); 3.13 (t, 2H, J = 6.8 Hz, CH2); 4.27 (s, 2H, CH2); 6.97 (s, 1H); 7.20 (t, 1H, J = 7.2 
Hz); 7.33-7.48 (m, 4H); 7.64 (d, 1H, J=7.8 Hz); 7.74 (d, 1H, J=8.2 Hz); 7.84 (d, 1H, J=7.8 Hz); 8.00 
(d, 2H, J=4.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 25.7, 49.8, 51.4, 111.1, 113.9, 118.9, 119.3, 121.9, 
122.0, 123.5, 125.4, 125.5, 125.9, 126.0, 127.4, 127.7, 128.7, 131.7, 133.8, 135.7. ESIMS m/z calcd for 
C21H20N2, 300.16; found 301.18 (M+H
+
). 
2-(1H-Indol-3-yl)-N-[(7-methoxynaphthalen-1-yl)methyl]ethanamine (16). 
Synthesized starting from 13 and 2-methoxy-1-naphthaldehyde, yield 63%. 
1
H NMR (400 MHz, 
CDCl3)  3.05-3.09 (m, 4H, CH2); 3.61 (s, 3H, CH3); 4.35 (s, 2H, CH2); 7.01-7.19 (m, 3H); 7.28-7.44 
(m, 6H); 7.76 (d, 1H, J=7.8 Hz); 7.90 (d, 1H, J=7.0 Hz); 8.14 (s, 1H, NH). 
13
C NMR (100 MHz, 
 CDCl3) δ 25.1; 42.6; 48.1; 56.0; 94.6, 111.4; 112.7; 119.0, 119.6, 122.3, 122.7, 122.9; 123.6; 127.3; 
128.8; 129.9; 130.7; 131.7; 136.5, 142.8. ESIMS m/z calcd for C21H20N2O 330.17; found 331.21 
(M+H
+
). 
1-[(2-(1H-Indol-3-yl)ethyl)amino]methyl]naphthalen-2-ol (17). 
Synthesized starting from 13 and 2-hydroxy-1-naphthaldehyde, yield 51%. 
1
H NMR (400 MHz, 
CDCl3)  3.05-3.09 (m, 4H, 2CH2); 4.41 (s, 2H, CH2); 7.07-7.14 (m, 3H); 7.20 (t, 1H, J = 7.0 Hz); 
7.26-7.42 (m, 3H); 7.60 (d, 1H, J=8.0 Hz); 7.65 (d, 1H, J=8.0 Hz); 7.73 (d, 2H, J=8.0 Hz); 8.08 (s, 1H, 
NH) 
13
C NMR (100 MHz, CDCl3) δ 25.2; 47.4; 48.7; 111.4; 111.5; 112.8; 113.0; 118.9, 119.6, 119.7, 
121.1, 122.5; 122.6; 126.6; 127.5; 128.6; 129.0; 129.3; 131.9; 137.4, 142.7. ESIMS m/z calcd for 
C21H20N2O, 316.16; found 317.40 (M+H
+
). 
2-(1H-Indol-3-yl)-N-[(10-methylanthracen-9-yl)methyl]ethanamine (18). 
Synthesized starting from 13 and 10-methyl-9-anthracenecarbaldehyde, yield 58%. 
1
H NMR (400 
MHz, CDCl3) 3.07 (m, 4H, 2CH2); 3.26 (t, 2H, J = 6.4 Hz, CH2); 3.48 (s, 3H, CH3); 6.92 (s, 
1H); 7.10 (t, 1H, J = 8.0 Hz); 7.20 (t, 1H, J = 8.0 Hz); 7.32 (d, 1H, J=8.0 Hz); 7.39 (t, 2H, J = 7.8 Hz); 
7.46 (t, 2H, J = 8.0 Hz, aryl); 7.56 (d,1H, J=8.0 Hz); 7.95 (s, 1H, NH); 8.19 (d, 2H, J=8.0 Hz); 8.29 (d, 
2H, J=8.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 17.1; 25.5; 45.6; 49.7; 111.4; 111.5;112.2; 113.0; 119.7, 
122.2, 122.4, 124.6; 125.0; 125.7; 125.9; 136.5; 142.7. ESIMS m/z calcd for C26H24N2, 364.19 found 
365.48 (M+H
+
). 
5[(2-(1H-Indol-3-yl)ethylamino)methyl]-2-methoxyphenol (19). 
Synthesized starting from 13 and vanillin, yield 58%. 
1
H NMR (400 MHz, CD3OD)  (t, 2H, 
CH2, J=7.4 Hz ); 2.92 (t, 2H, CH2, J=7.4 Hz); 3.59 (s, 2H, CH2); 3.67 (s, 3H, CH3); 6.61 (d, 1H, J=8.0 
Hz ); 6.71 (s, 1H); 6.73 (d, 1H, J=8.0 Hz); 6.94-6.98 (m, 2H); 7.05 (t, 1H, J=8.0 Hz); 7.31 (d, 1H, 
J=8.0 Hz); 7.48 (d, 1H, J=8.0 Hz). 
13
C NMR (100 MHz, CD3OD) δ 24.7, 48.6, 52.8, 55.1, 111.2, 
 111.8, 112.1, 115.0, 118.2, 121.2, 121.3, 122.4, 122.5, 127.4, 130.1, 137.0, 145.9, 147.9. ESIMS m/z 
calcd for C18H20N2O2, 296.15; found 297.16 (M+H
+
). 
N-(3,4-Dimethoxybenzyl)-2-(1H-indol-3-yl)ethanamine (20). 
Synthesized starting from 13 and 3,4-dimethoxybenzaldehyde, yield 72%. 
1
H NMR (400 MHz, CDCl3) 
 3.01-3.15 (m, 4H, 2CH2); 3.80 (s, 2H, CH2); 3.82 (s, 6H , 2CH3); 6.75 (d, 1H, J=8.0 Hz); 6.81 (d, 1H, 
J=8.0 Hz); 6.88 (s, 1H); 7.03 (s, 1H); 7.10 (t, 1H, J=4.0 Hz); 7.18 (t, 1H, J=4.0 Hz); 7.35 (d, 1H, J=8.0 
Hz); 7.58 (d, 1H, J=8.0 Hz); 8.10 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 25.4; 49.0; 53.5; 56.0; 
111.0, 111.4; 111.5; 112.7; 119.0, 119.5, 120.8, 122.3; 122.4; 127.4; 130.1; 137.0; 145.9, 147.9. 
ESIMS m/z calcd for C19H22N2O2, 310.17; found 311. 25 (M+H
+
). 
2-(1H-Indol-3-yl)-N-(4-phenoxybenzyl)ethanamine (21) 
Synthesized starting from 13 and 4-phenoxybenzaldehyde, yield 83%. 
1
H NMR (400 MHz, CD3OD)  
3.12 (t, 2H, CH2, J=8.8 Hz); 3.24 (t, 2H, CH2, J=8.4 Hz); 4.08 (s, 2H , CH2); 6.95-7.05 (m, 5H); 7.10-
7.18 (m, 3H); 7.31-7.42 (m, 5H); 7.53 (d, 1H, J=8.0 Hz). 
13
C NMR (100 MHz, CD3OD) δ 24.5; 50.7; 
52.7; 111.4; 113.4; 119.8; 120.6; 120.9, 121.3, 123.6, 124.9; 125.9; 128.8; 129.0; 131.9; 133.4; 139.2; 
158.8, 160.8. ESIMS m/z calcd for C23H22N2O, 342.17; found 343. 25 (M+H
+
) 
N-Methyl-2-(1-methyl-1H-indol-3-yl)-N-(4-phenoxybenzyl)ethanamine (22) 
Compound 21 (1 eq) was dissolved in a mixture of anhydrous DCM/DMF (2/1 v/v) under magnetic 
stirring and the temperature was set to 0°C. To this solution, 3 equivalents of NaH were added 
portionwise and the mixture was allowed to react for 30 minutes. Then, 3 equivalents of methyl iodide 
in dry DCM were added dropwise and the reaction was warmed to room temperature and maintained 
under stirring for further 12h. Then, reaction was quenched by 10% aqueous solution of citric acid and 
washed with brine. Organic layer was separated, dried over anhydrous Na2SO4, filtered and evaporated 
in vacuo. Crude product was purified by column chromatography using DCM/MeOH (9:1 v:v) as 
mobile phase.
 1
H NMR (400 MHz ,CDCl3) δ 3.14-3.18 (m, 5H, CH3 and CH2); 3.78 (s, 3H, CH3); 3.84 
 (t, 2H, J = 8.0 Hz, CH2); 4.99 (s, 2H, CH2); 6.95 (d, 2H, J=8.0 Hz); 7.05 (d, 2H, J=8.0 Hz); 7.17 (t, 1H, 
J=7.6 Hz); 7.18-7.24 (m, 4H); 7.35 (t, 2H, J = 8.0 Hz); 7.59 (d, 3H, J = 8.0 Hz). 
13
C NMR (100 MHz, 
CDCl3) δ 19.3, 32.8, 49.7, 63.7, 67.0, 109.5, 118.2, 118.4, 119.3, 119.9, 120.7, 121.9, 124.5, 126.9, 
128.2, 130.0, 134.8, 136.8, 155.4, 159.9. ESIMS m/z calcd for C25H26N2O, 370.49; found 371.55 
(M+H
+
). 
 
Pharmacology 
Cell culture and transfections  
 For fluorescence assays, cells stably expressing TRP channels (SH-SY5Y for TRPV1, HEK for 
TRPM8 and IMR90 for TRPA1) were cultured in a monolayer at 37ºC in a humidified atmosphere of 
5% CO2 in Earle’s minimum essential medium with Earle’s salts supplemented with 10% fetal calf 
serum,1% nonessential amino acids, 2 mM L-glutamine, 100 µg streptomycin/ml, 100 U penicillin/ml, 
and the correspondent antibiotic for each stable cell line (0.4 µg/ml puromycin for Sh-SY5Y and 400 
g/ml G418 for HEK-CR1).  
 For electrophysiological experiments, HEK293 cells were grown in 100-mm plastic Petri dishes 
in Dulbecco’s modified Eagle medium containing 10% fetal bovine serum, penicillin (100 U/ml), and 
streptomycin (100 U/ml) in a humidified atmosphere at 37°C with 5% CO2. The cells were seeded on 
glass coverslips (Carolina Biological Supply Company, Burlington, NC) and transfected the next day 
with 3.6 µg rat TRPM8 receptor cDNA (a gift from Dr. Felix Viana, Alicante Institute of 
Neuroscience, Elche, Spain) using Lipofectamine 2000 (Invitrogen, Milan, Italy). A plasmid encoding 
for the Enhanced Green Fluorescent Protein (Clontech, Palo Alto, CA) was used as a transfection 
marker. Total cDNA in the transfection mixture was kept constant at 4 μg.  
 
Fluorescence assays. 
  For fluorescence assays, the cells were seeded in 96-well plates (Corning Incorporated, 
Corning, NY) at a cell density of 40,000 cells 2 days before treatment. The day of treatment the 
medium was replaced with 100 L of the dye loading solution Fluo-4 NW supplemented with 
probenecid 2.5 mM. Then the tested molecules dissolved in DMSO were added at the desired 
concentrations and the plate(s) were incubated in darkness at 37°C in a humidified atmosphere of 5% 
CO2 for 60 minutes. The fluorescence was measure using instrument settings appropriate for excitation 
at 485 nm and emission at 535 nm. (POLARstar Omega BMG LAB tech). A baseline recording of 4 
cycles was recorded prior to stimulation with the agonist (10 M capsaicin for TRPV1, 100 M 
menthol for TRPM8, and 100 M AITC for TRPA1). Each antagonist (10 M Ruthenium Red for 
TRPV1 and TRPA1, 10 M AMTB for TRPM8) was added to the medium containing the 
corresponding agonist to induce channel blockade. The changes in fluorescence intensity were recorded 
during 15 cycles more. The higher concentration of DMSO used in the experiment, was added to the 
control wells.  
The cells fluorescence was measured before and after the addition of various concentrations of test 
compounds (EX = 488 nm, EM = 516 nm). The fluorescence values obtained are normalized to that 
prompted by the corresponding agonist (for channel activating compounds) or upon agonist+antagonist 
co-exposure (for channel blocker compounds).  
 
 Whole-cell electrophysiology 
  Macroscopic currents from transiently transfected HEK293 cells were recorded at room 
temperature 1 day after transfection, with an Axopatch 200B amplifier (Molecular Devices, Union 
City, CA) using the whole-cell configuration of the patch-clamp technique, with glass micropipettes of 
3-5 M resistance. The extracellular solution contained (mM): 138 NaCl, 2 CaCl2, 5.4 KCl, 1 MgCl2, 
10 glucose, and 10 HEPES, pH 7.4 with NaOH. The pipette (intracellular) solution contained (mM): 
 140 CsCl, 1 EGTA, 10 HEPES, and 5 Mg-ATP, pH 7.3-7.4 with CsOH. The pCLAMP software 
(version 10.2; Molecular Devices) was used for data acquisition and analysis. Linear cell capacitance 
(C) was determined by integrating the area under the whole-cell capacity transients, evoked by short (5-
10 ms) pulses from -80 to -75 mV with the whole-cell capacitance compensation circuit of the 
Axopatch 200B turned off. Data were acquired at 5 kHz and filtered at 1-5 kHz with the four-pole 
lowpass Bessel filter of the amplifier. No corrections were made for liquid junction potentials. Currents 
were evoked by consecutive voltage ramps from -100 to +100 mV in 100 ms, delivered every 4 
seconds. Current densities (expressed in pA/pF) were calculated at +80mV or -80 mV and divided by 
C. 
 
 Chemical modulators 
  l-Menthol and BCTC were purchased from Applichem Panreac (Barcelona, Spain) and Tocris 
Bioscience (Bristol, UK), respectively; AITC, Capsaicin and ruthenium red were purchased from 
Sigma-Aldrich (St.Louis, MO, USA). These compounds were dissolved in DMSO (final concentration 
≤ 1%). In each experiment, the same volume of solvent used for tested drugs was added to the control 
solution. Fast solution exchanges (<1 s) were achieved by means of a cFlow 8 flow controller attached 
to a cF-8VS 8-valve switching apparatus, as previously described. 
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Molecular modeling  
Protein and ligands preparations 
 The TRPM8 homology model 
30
 was prepared using the Protein Preparation
38,39
 utility in order 
to obtain satisfactory starting structures for the following studies. This utility is meant to ensure 
chemical correctness and to optimize protein structures for further analysis. In particular, Epik
40
 was 
 then used to predict ionization and tautomeric states for the ligands using a pH of 7±1. Successively, 
optimization of the hydrogen-bonding network was obtained by reorienting hydroxyl and thiol groups, 
amide groups of Asn and Gln, and His rings. The ionization and tautomeric states of His, Asp, Glu, Arg 
and Lys were adjusted to match a pH of 7.4. The structure was finally submitted to a restrained 
minimization (OPLS2005 force field)
41
 that was stopped when RMSD of heavy atoms reached 0.30 Å. 
Ligands were sketched using the Maestro
42
 interface and 3D coordinates were generated using 
LigPrep
43
 Ionization/tautomeric states were predicted for a pH range of 7±1 using Epik.
 40
 The most 
populated ionization state for each ligand was retained. 
Sitemap calculations 
All TRPM8 atoms were considered in the identification the top ranking potential binding sites. Each 
site was required to have at least 5 site points and was cropped at 4 Å from the nearest site point. The 
definition of hydrophobicity was set to “restrictive”. 
Molecular docking 
Docking of 12 and 21 was performed using Glide SP
44–46
 and XP
47
 in a stepwise manner. The docking 
spaces was defined as as a 50Å
3
 cubic box, while the diameter midpoint of docked ligands was required 
to remain within a smaller, nested 30Å
3
 cubic box centered on the centroid of BP1 site points. Receptor 
OH and SH groups were set free to rotate. Two docking grids were used for SP and XP docking, 
differing for the scaling of vdW radii for non polar receptor atoms only. For SP a coefficient of 0.85 
was used, while no scaling was used for XP.  
At most ten poses for each ligand were retrieved from the SP docking, discarding as duplicates poses 
that showed both RMS deviation less than 1.5Å and maximum atomic displacement less than 2.0Å. 
These poses were then refined, rescored and minimized using Glide XP. The best scoring XP pose for 
each ligand was then retained for the MD simulations.  
Molecular dynamics simulation 
 MD simulations of TRPM8/12 and TRPM8/21 complexes were set and run using Desmond MD 
system
48–50
. The simulated environment was built using the system builder utility, with the structures 
being neutralized by Cl
-
 ions. The small 903-924 fragment was removed. With the exception of the 
954-1016 fragment, which was uncostrained, the protein backbone was constrained by a 1 kcal/mol 
force. Octanol was used as explicit solvent. Before performing the simulations, a series of 
minimizations and short MD simulations were carried out to relax the model system, by means of a 
relaxation protocol consisting of six stages: (i) minimization with the solute restrained; (ii) 
minimization without restraints; (iii) simulation (12 ps) in the NVT ensemble using a Berendsen 
thermostat (10 K) with non-hydrogen solute atoms restrained; (iv) simulation (12 ps) in the NPT 
ensemble using a Berendsen thermostat (10 K) and a Berendsen barostat (1 atm) with non-hydrogen 
solute atoms restrained; (v) simulation (24 ps) in the NPT ensemble using a Berendsen thermostat (300 
K) and a Berendsen barostat (1 atm) with non-hydrogen solute atoms restrained; (vi) unrestrained 
simulation (24 ps) in the NPT ensemble using a Berendsen thermostat (300 K) and a Berendsen 
barostat (1 atm). At this point, 12ns long MD simulations were carried out at a temperature of 300° K 
in the NPT ensemble using a Nose-Hoover chain thermostat and a Martyna-Tobias-Klein barostat 
(1.01325 bar). Trajectory analyses were performed using the Desmond simulation event analysis tool 
for the RMSD calculations, Desmond Simulation Interaction diagram tool for the Ligand Interaction 
analysis and Schrodinger clustering of conformers script for the bound conformation analysis.  
 Pharmacophore modeling 
Docking/MD predicted bound conformations were used to manually build the pharmacophore models 
summarizing the chemical feature of tryptamine based agonists and antagonists. Models were built 
using the software Phase.
51–53
 Features and their coordinates were automatically detected using the 
ligand-based option of Phase and were then edited in freestyle modes according to the ligand-protein 
interaction detected by the Simulation Interaction diagram tool. In particular, H1 and H2 features were 
 previously detected as aromatic features, but were changed to hydrophobic since during the MD 
trajectories they interacted with non aromatic hydrophobic residues only. For the same reason, the R3 
feature of the antagonist model was changed to H1. After the model generation and refinement phase 
was used to evaluate the fitness of the tryptamine based agonists and antagonists on the two models as 
reported in Table S1. 
 
Statistical analysis 
 Data are expressed as mean ± SEM. Statistically significant differences were evaluated with the 
Student t test or with ANOVA followed by the Student-Newman-Keuls test, with the threshold set at 
p<0.05. 
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 ABREVIATIONS  
TRP box, structuralmotif in the cytosolic C-terminus domain of TRP channel; VSD voltage sensor 
domain of TRP channels; DCM, dichloromethane; DMF, dimethylformamide; NaH, hydride sodium; 
THF,  tetrahydrofuran;  TEA, triethylamine; mW, microwave; TRPV1, transient receptor potential 
cation channel subfamily V member 1; TRPA1, transient receptor potential cation channel, subfamily 
A, member 1; AITC, allyl isothiocyanate; BCTC, N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-
yl)piperazine-1-carboxamide; BP1, potential binding site;  SEM, standard error of the mean; MS, mass 
spectrometry; ESI, electrospray ionization; MeOH methanol; DMSO, dimethylsulfoxide; HEPES, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid; EGTA, ethylene glycol tetraacetic acid; RMSD, root-
mean-square deviation. 
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